Avacta Group Plc (OTCMKTS:AVCTF – Get Free Report) was the target of a significant drop in short interest in June. As of June 30th, there was short interest totaling 31,567 shares, a drop of 62.2% from the June 15th total of 83,496 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.
Avacta Group Stock Performance
Shares of AVCTF stock opened at $1.00 on Tuesday. Avacta Group has a fifty-two week low of $0.45 and a fifty-two week high of $1.23. The stock’s 50-day simple moving average is $1.03 and its 200-day simple moving average is $0.91.
About Avacta Group
Avacta Group plc is a UK-based biotechnology company specializing in the discovery, development and commercialization of Affimer® biotherapeutics and diagnostic reagents. The company’s proprietary Affimer platform uses small, engineered protein scaffolds that can be tailored to bind specifically to target molecules, offering an alternative to traditional antibodies. Avacta operates two core divisions: Avacta Therapeutics, which focuses on novel treatments in oncology and immune-related diseases, and Avacta Analytical, which develops reagents and point-of-care diagnostic tests.
In its diagnostics business, Avacta has applied the Affimer technology to lateral flow assays, most notably for rapid detection of viral pathogens such as SARS-CoV-2.
Featured Stories
- Five stocks we like better than Avacta Group
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
